Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Otorhinolaryngol. Apr 27, 2019; 8(1): 1-3
Published online Apr 27, 2019. doi: 10.5319/wjo.v8.i1.1
CX3CR1 receptor as a potential therapeutic target in chronic rhinosinusitis and allergic rhinitis
Amr El-Shazly
Amr El-Shazly, Department of Otolaryngology, Liège University Hospital, Liège 4000, Belgium
Author contributions: El-Shazly A contributed to the manuscript.
Conflict-of-interest statement: No potential conflicts of interest relevant to this article were reported.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Amr El-Shazly, MD, PhD, Professor, Department of Otolaryngology, Liège University Hospital, Laboratory of Experimental Pathology-Experimental Rhinology Unit, Liège 4000, Belgium. amrel_shazly@hotmail.com
Telephone: +32-4-3662111
Received: June 15, 2018
Peer-review started: June 15, 2018
First decision: August 9, 2018
Revised: January 23, 2019
Accepted: March 15, 2019
Article in press: March 16, 2019
Published online: April 27, 2019
Core Tip

Core tip: In this editorial, we explore the role of CX3CR1 as therapeutic target in diseases, characterized by recruitment of inflammatory such as chronic rhinosinusitis and allergic rhinitis. Both diseases are chronic inflammatory diseases that affect the mucous membrane of the nose and paranasal sinuses. In this editorial, the novel role of CX3CR1 receptor in the immunopathology of chronic inflammation of the nose and paranasal sinuses will be explored with its potential role as therapeutic target in chronic nasal inflammation.